Literature DB >> 19635394

S-Adenosylhomocysteine increases beta-amyloid formation in BV-2 microglial cells by increased expressions of beta-amyloid precursor protein and presenilin 1 and by hypomethylation of these gene promoters.

Hung-Chi Lin1, Huei-Min Hsieh, Yu-Hsuan Chen, Miao-Lin Hu.   

Abstract

S-Adenosylhomocysteine (SAH) has been implicated as a risk factor for neurodegenerative diseases such as Alzheimer's disease. As SAH is a potent inhibitor of all cellular methyltransferases, we herein examined the hypothesis that SAH may increase the formation of amyloid beta-peptide (Abeta) in BV-2 mouse microglial cells through hypomethylation of presenilin 1 protein (PS1) and beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), both of which cleave Abeta precursor protein (APP) to form Abeta. The results showed that SAH increased Abeta protein formation in a concentration-dependent manner (10-500 nM), and this effect of SAH was accompanied by significantly increased expression of APP and PS1 proteins, although SAH only significantly increased the expression of BACE1 at the highest concentration used (500 nM). SAH (500 nM) markedly induced hypomethylation of APP and PS1 gene promoters. Incubation of cells with 5'-azc (20 microM), also an inhibitor of DNA methyltransferases enhanced Abeta protein expression and APP and PS1 gene promoters hypomethylation. By contrast, pre-incubation of cells with betaine (1.0 mM), 30 min followed by incubation with SAH (500 nM) or 5'-azc (20 microM) for 24h markedly prevented the expression of Abeta protein (by 50%, P<0.05) and the gene promoter hypomethylation of APP and PS1. Taken together, this study demonstrates that SAH increases the production of Abeta in BV-2 cells possibly by increased expression of APP and induction of hypomethylation of APP and PS1 gene promoters.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19635394     DOI: 10.1016/j.neuro.2009.03.011

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  24 in total

Review 1.  Folate and Alzheimer: when time matters.

Authors:  Margareta Hinterberger; Peter Fischer
Journal:  J Neural Transm (Vienna)       Date:  2012-05-25       Impact factor: 3.575

2.  Formaldehyde, Epigenetics, and Alzheimer's Disease.

Authors:  Fei Wang; Danqi Chen; Peipei Wu; Catherine Klein; Chunyuan Jin
Journal:  Chem Res Toxicol       Date:  2019-04-19       Impact factor: 3.739

Review 3.  Epigenetics and the modulation of neuroinflammation.

Authors:  Gwenn A Garden
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 4.  Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?

Authors:  Jia-Min Zhuo; Hong Wang; Domenico Praticò
Journal:  Trends Pharmacol Sci       Date:  2011-06-20       Impact factor: 14.819

5.  Recognition of betaine as an inhibitor of lipopolysaccharide-induced nitric oxide production in activated microglial cells.

Authors:  Banafsheh Amiraslani; Farzaneh Sabouni; Shahsanam Abbasi; Habiballah Nazem; Mohammadsadegh Sabet
Journal:  Iran Biomed J       Date:  2012

6.  Folate deficiency exacerbates apoptosis by inducing hypomethylation and resultant overexpression of DR4 together with altering DNMTs in Alzheimer's disease.

Authors:  Yun Wang; Shunliang Xu; Yanjun Cao; Zhaohong Xie; Chao Lai; Xiaowei Ji; Jianzhong Bi
Journal:  Int J Clin Exp Med       Date:  2014-08-15

Review 7.  Epigenetics in Alzheimer's Disease: Perspective of DNA Methylation.

Authors:  Talal Jamil Qazi; Zhenzhen Quan; Asif Mir; Hong Qing
Journal:  Mol Neurobiol       Date:  2017-01-14       Impact factor: 5.590

8.  CpG and non-CpG Presenilin1 methylation pattern in course of neurodevelopment and neurodegeneration is associated with gene expression in human and murine brain.

Authors:  Noemi Monti; Rosaria A Cavallaro; Andrea Stoccoro; Vincenzina Nicolia; Sigfrido Scarpa; Gabor G Kovacs; Maria Teresa Fiorenza; Marco Lucarelli; Eleonora Aronica; Isidre Ferrer; Fabio Coppedè; Aron M Troen; Andrea Fuso
Journal:  Epigenetics       Date:  2020-02-05       Impact factor: 4.528

Review 9.  Epigenetics of Alzheimer's disease and frontotemporal dementia.

Authors:  Chendhore S Veerappan; Sama Sleiman; Giovanni Coppola
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

10.  One-carbon metabolism and Alzheimer's disease: focus on epigenetics.

Authors:  Fabio Coppedè
Journal:  Curr Genomics       Date:  2010-06       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.